Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted to significantly impact asthma and other respiratory-related conditions, as rising global temperatures lead to longer pollen […]

Search Results

Showing Results for Chronic obstructive pulmonary disease

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Explore expert perspectives from ATS 2025 with our exclusive interview series. Discover key advances in respiratory care, including updates on COPD, ILD, ventilation strategies, and emerging therapies. Stay informed with concise, clinically relevant insights tailored for healthcare professionals on touchRESPIRATORY.

Coverage from: ATS Highlights

In this Q&A, Professors David Price and David Halpin discuss their ATS 2025 abstract on improving COPD outcomes through a digital adherence support package. They explore the MAGNIFY trial's design, including how an EMR-driven algorithm identified high-risk patients and how a pharmacist-led intervention combined with a digital inhaler device significantly reduced treatment failure in a real-world primary care setting.

Mark CompleteCompleted
BookmarkBookmarked

Ventilator-associated pneumonia (VAP) poses a serious threat in ICUs, often driven by biofilms on endotracheal tubes that resist antibiotics. In this Q&A, Professor Frank MP van Haren discusses a study showing that nebulized BromAc® effectively disrupts these biofilms and enhances antibiotic action, offering a promising strategy against persistent infections like Pseudomonas aeruginosa-related VAP.

Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted ...

Mark CompleteCompleted
BookmarkBookmarked

For patients living with chronic respiratory diseases (CRDs) such as chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD), access to reliable and comprehensive health information is often limited and unreliable.

Mark CompleteCompleted
BookmarkBookmarked

As we observe World Lung Day, it is crucial to reflect on the escalating impact of respiratory diseases across the globe. Chronic respiratory diseases — including chronic obstructive pulmonary disease (COPD), asthma, lung cancer, pulmonary hypertension, obstructive sleep apnea, and others — continue to rank among the leading causes of morbidity and mortality worldwide. The World Health Organization’s latest data underscores the persistence of the global respiratory crisis:

Developed by Touch
Coverage from: Key congresses 2024

The BETTER-B study, recently presented at ERS and published in The Lancet Respiratory Medicine, provided new insights into the management of severe breathlessness in patients with chronic respiratory diseases such as COPD and Interstitial Lung Disease (ILD).  Severe breathlessness is a debilitating symptom that significantly impacts the quality of life for millions of people worldwide, yet there are currently no licensed medications to effectively address it outside of Australia. Given the clinical challenges and limited treatment options, clinicians often resort to off-label use of medications like mirtazapine, a widely prescribed antidepressant that appeared promising. Despite its initial promise, the study found that doses ranging from 15 to 45 mg of mirtazapine failed to provide significant relief compared to a placebo. Additionally, the findings highlighted potential adverse effects and increased healthcare costs associated with its use. 

Mark CompleteCompleted
BookmarkBookmarked

The European Commission has approved dupilumab (Regeneron and Sanofi)) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and ...

Mark CompleteCompleted
BookmarkBookmarked

Approximately half of all smokers will develop chronic obstructive pulmonary disease (COPD), with a disease progression over several years before the spirometric threshold for diagnosis is reached.1 There is, therefore, a clear benefit in identifying patients with COPD as early ...

Mark CompleteCompleted
BookmarkBookmarked

The nasal airway serves as the primary entry point of air and oxygen into the body. It serves critical functions, such as providing a physical barrier against external irritants and pathogens and warming and humidifying incoming air.1 Consequently, disorders of ...

Mark CompleteCompleted
BookmarkBookmarked

Paediatric sleep-disordered breathing Sleep-disordered breathing (SDB) is defined as the disruption of normal respiration and ventilation while asleep.1 SDB encompasses multiple sleep disturbances, ranging from mild snoring to obstructive sleep apnoea (OSA).1,2 OSA is characterized by episodic partial or complete ...

Mark CompleteCompleted
BookmarkBookmarked

Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1 Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...

Mark CompleteCompleted
BookmarkBookmarked

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are the dominant cause of the worsening and high mortality of chronic obstructive pulmonary disease (COPD), and are associated with higher healthcare costs as part of COPD management. AECOPD is characterized by ...

Developed by Touch
Coverage from: ERS Highlights

Altitude can exacerbate chronic obstructive pulmonary disease (COPD symptoms) and has associated adverse health effects. We are joined by Dr Michael Furian (University of Zurich, Zurich, Switzerland) to explore the adverse health effects and significant influence on patient quality of ...

Mark CompleteCompleted
BookmarkBookmarked
Laurence Désy, Philippe Lachapelle, Simon Couillard

The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare ...

Developed by Touch
Coverage from: ATS Highlights

The phase 3 BOREAS study (NCT03930732) investigated the efficacy and safety of dupilumab for the treatment of chronic obstructive pulmonary disease with type 2 inflammation. It was a pleasure to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the ...

Developed by Touch
Coverage from: ATS Highlights

Dupilumab is an investigational monoclonal antibody that mitigates type 2 inflammation by blocking IL-4 and IL-13 receptors in patients with COPD. We were delighted to talk with Prof. Klaus F. Rabe (University of Kiel, Germany) around the unmet needs in the ...

Load More...
Close Popup